儿童急诊科儿童哮吼合并COVID-19疾病严重程度与结局的预测因素
本研究在两家儿童急诊科纳入250例SARS-CoV-2所致哮吼患儿,分析年龄、WS、住院时间、初始实验室指标与治疗等临床数据,采用多因素logistic回归和ROC曲线评估预测因素。结果显示,较高平均年龄、中性粒细胞计数(%)、NLR、ALT(U/L)、降钙素原(ng/mL)、血红蛋白(g/dL)、住院时间(天)以及较低淋巴细胞计数(%)和血pH与哮吼严重程度及需要重症监护相关;多因素模型中NLR为与哮吼严重程度和预后相关的独立因素。NLR预测WS≥3的AUC为0.895(0.842-0.948,p<0.001),预测ICU入院的AUC为0.795(0.711-0.879,p<0.001),最佳截断值分别为1.65和2.06。作者认为NLR是儿童急诊科早期筛查和预后评估哮吼严重程度的可靠、易用且廉价的生物标志物,WS对评估SARS-CoV-2所致哮吼严重程度和重症监护风险仍可靠。
要点
- 250例SARS-CoV-2所致哮吼患儿中,轻度占63.6%(n=159)、中度占32%(n=80)、重度占4.4%(n=11)。
- 128例(51.2%)从儿童急诊科离院,122例(48.8%)收入院。
- NLR预测WS≥3的AUC为0.895(0.842-0.948,p<0.001),最佳截断值1.65。
- NLR预测ICU入院的AUC为0.795(0.711-0.879,p<0.001),最佳截断值2.06。
- 多因素logistic回归模型中,NLR仍为与哮吼严重程度和预后相关的独立因素。
适用人群与场景
- 在两家儿童急诊科(PED)就诊并诊断为SARS-CoV-2所致哮吼的患儿,共250例。
诊断标准与关键阈值
- 采用Westley哮吼评分(WS)评估哮吼严重程度,WS≥3为预测严重程度的判定界值。
- NLR预测WS≥3的最佳截断值为1.65,预测ICU入院的最佳截断值为2.06。
红旗征与不能漏的情况
- WS≥3提示哮吼严重程度较高,NLR≥1.65预测WS≥3的AUC为0.895(0.842-0.948,p<0.001)。
- NLR≥2.06预测ICU入院的AUC为0.795(0.711-0.879,p<0.001)。
研究设计与关键结果
- 共评估250例患儿,128例(51.2%)从儿童急诊科离院,122例(48.8%)收入院;轻度、中度、重度哮吼分别占63.6%(n=159)、32%(n=80)、4.4%(n=11)。
- 较高的平均年龄(岁)、中性粒细胞计数(%)、NLR、ALT(U/L)、降钙素原(ng/mL)、血红蛋白(g/dL)、住院时间(天),以及较低的淋巴细胞计数(%)和血pH与哮吼严重程度及需要重症监护相关。
- 多因素logistic回归模型显示,NLR仍为与哮吼严重程度和预后相关的独立因素;NLR与WS显著相关。
- NLR预测WS≥3的ROC曲线下面积为0.895(0.842-0.948,p<0.001),预测ICU入院的ROC曲线下面积为0.795(0.711-0.879,p<0.001);WS≥3和ICU入院的最佳截断值分别为1.65和2.06。
证据类型、等级与局限
- 研究类型:在两家儿童急诊科开展的临床研究,样本量250例。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为NLR与WS相关,是儿童急诊科早期筛查和预后评估哮吼严重程度的可靠、易用且廉价的生物标志物。
- 作者认为较高的NLR可能提示重度哮吼和需要进一步治疗。
- 作者认为WS对评估SARS-CoV-2所致哮吼的严重程度和重症监护风险仍可靠。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Croup caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging disease, and data on the risk factors associated with disease severity are still limited. The Westley croup score (WS) is widely used to assess croup severity. The current study aimed to analyze biomarkers associated with the WS and clinical outcomes in patients with croup and coronavirus disease 2019 in the pediatric emergency department (PED).
POPULATION AND METHOD: Patients diagnosed with croup caused by SARS-CoV-2 were admitted at two PEDs. Clinical data including age, WS, length of hospital stay, initial laboratory data, and treatment were analyzed. Clinical parameters were evaluated via multivariate logistic regression analysis. The best cutoff values for predicting croup severity and outcomes were identified using the receiver operating characteristic curve.
RESULT: In total, 250 patients were assessed. Moreover, 128 (51.2%) patients were discharged from the PED, and 122 (48.8%) were admitted to the hospital. Mild, moderate, and severe croup accounted for 63.6% (n = 159), 32% (n = 80), and 4.4% (n = 11) of all cases, respectively. A high mean age (years), neutrophil count (%), neutrophil-to-lymphocyte ratio (NLR), ALT (U/L), procalcitonin (ng/mL), and hemoglobin (g/dL) level, and length of hospital stay (days), and a low lymphocyte count (%) and blood pH were associated with croup severity and need for intensive care. Based on the multivariate logistic regression model, the NLR remained independent factors associated with croup severity and prognosis. Further, NLR was significantly correlated with WS. The area under the receiver operating characteristic curve of NLR for predicting a WS of ≥3 was 0.895 (0.842-0.948, p < 0.001), and that for predicting ICU admission was 0.795 (0.711-0.879, p < 0.001). The best cutoff values for a WS of ≥3 and ICU admission were 1.65 and 2.06, respectively.
CONCLUSION: NLR is correlated with WS and is a reliable, easy-to-use, and cheap biomarker for the early screening and prognosis of croup severity in the PED. A higher NLR may indicate severe croup and the need for further treatment. And the WS score remains reliable for estimating the severity of croup caused by SARS-CoV-2 and the risk of intensive care.
参考来源
- Lee EP, Mu CT, Yen CW, et al. Predictors of disease severity and outcomes in pediatric patients with croup and COVID-19 in the pediatric emergency department. Am J Emerg Med. 2023. PMID: 37453221. doi:10.1016/j.ajem.2023.06.050
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。